Matricelf Ltd Share Price OTC Markets

MTRLF

IL0011767915

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 11:57:58 25/08/2022 pm IST			5-day change	1st Jan Change
1.900 ^USD	-40.99%		-.--%	-

09/07	Matricelf Ltd. Receives Approval to Begin Patient Identification and Blood Collection for Planned First-In-Human Spinal Cord Injury Study	CI
22/06	Matricelf Initiates Ind Enabling Efficacy Study for Engineered Human Neural Tissue Implant in Chronic Spinal Cord Injury	CI

Matricelf Ltd is an Israel-based company engaged in the biotechnology sector. The Company operates in the field of tissue engineering and regenerative medicine. The Firm develops a platform for autologous 3D printing of neutral human matrix, cells, tissues and organs implants. The implants are manufactured using cellular components originated from the patients themselves, to reduce potential immune response. The Company focuses on the treatment of spinal cord injury (SCI), but is also involved in developing treatment for additional medical conditions, including: Myocardial Infarction (MI), Parkinsonâ€™s disease and Age-related Macular Degeneration (AMD). Matricelf Ltd is a spin-out company from Tel Aviv University.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Google lets you customize your preferred sources.

Choose MarketScreener

Market Cap	7.64Cr 2.51Cr 2.2Cr 2.03Cr 1.87Cr 3.52Cr 241.98Cr 3.6Cr 24Cr 9.53Cr 118.51Cr 9.44Cr 9.23Cr 407.97Cr	P/E 2024	-3.74x	P/E 2025	-3.65x
Enterprise Value	5.62Cr 1.85Cr 1.62Cr 1.49Cr 1.38Cr 2.59Cr 178.15Cr 2.65Cr 18Cr 7.01Cr 87Cr 6.95Cr 6.8Cr 300.36Cr	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	77.85%	Yield 2024 *	-	Yield 2025	-

09/07	Matricelf Ltd. Receives Approval to Begin Patient Identification and Blood Collection for Planned First-In-Human Spinal Cord Injury Study	CI
22/06	Matricelf Initiates Ind Enabling Efficacy Study for Engineered Human Neural Tissue Implant in Chronic Spinal Cord Injury	CI
17/06	Matricelf Completes GLP Safety Study for Engineered Neural Tissue Implant	CI
30/03	Matricelf Ltd. Enters into Collaborative Research Agreement with CiRA Foundation	CI
25/03	Matricelf Ltd Reports Earnings Results for the Full Year Ended December 31, 2025	CI
24/03	Matricelf and Sheba Medical Center Enter Strategic Collaboration to Advance First in Human Clinical Program in Spinal Cord Injury	CI
24/03	Matricelf Ltd Auditor Raises 'Going Concern' Doubt	CI
04/03	Matricelf Ltd. Reports Positive RNA Sequencing Results Demonstrating Promising Safety Profile Of Its Personalized Spinal Cord Implant	CI
03/03	Matricelf Ltd. Signs MOU to Establish Subsidiary for Commercialization of Parkinson's Disease Therapy	CI
03/03	Matricelf Ltd. (Tase Mtlf) signs MoU to establish subsidiary for commercialization of Parkinson's disease therapy	RE
27/02	Matricelf Ltd Appoints Ron Mayron as Active Chairman of the Board of Directors	CI
03/25/03	Matricelf Ltd Reports Earnings Results for the Half Year Ended June 30, 2025	CI
11/25/11	Cellino and Matricelf Announce Global Collaboration to Scale Personalized Spinal Cord Injury Treatments	CI

09/07	Matricelf Continues Clinical Execution with Patient Enrollment Preparation Following GLP Safety Success and GMP Manufacturing Milestones	PR
23/06	Matricelf Initiates IND Enabling Efficacy Study Following Positive Preclinical Results in Spinal Cord Injury	AQ
03/03	Matricelf Ltd. (TASE: MTLF) Signs MOU to Establish Subsidiary for Commercialization of Parkinson's Disease Therapy	PR
02/03	Matricelf Ltd. (TASE: MTLF) Appoints Ron Mayron as Chairman of the Board	AQ
27/02	Matricelf Ltd. (TASE: MTLF) Appoints Ron Mayron as Chairman of the Board	PR

5 years	1.9		3.22
10 years	1.9		3.22

Manager	Title	Age	Since
Asaf Toker CEO	Chief Executive Officer	53	01/06/2019
Tal Dvir CTO	Chief Tech/Sci/R&D Officer	51	01/06/2019
Alon Sinai COO	Chief Operating Officer	58	01/07/2019

Matricelf Ltd Share Price OTC Markets

Stocks

MTRLF

IL0011767915

Biotechnology & Medical Research

Valuation: Matricelf Ltd

Latest news : Matricelf Ltd

Press Releases: Matricelf Ltd

Quotes and Performance

Course Extremes

Managers and Directors: Matricelf Ltd

Other Biotechnology & Medical Research

Financials

Company Profile

Income Statement and Estimates

Director	Title	Age	Since
Alon Sinai BRD	Director/Board Member	58	01/07/2019
Tal Dvir BRD	Director/Board Member	51	01/06/2019
Stanley Hirsch BRD	Director/Board Member	68	27/07/2022

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MATRICELF LTD	-40.99%	-.--%	-	-	2.57Cr
LONZA GROUP AG	-1.29%	-2.54%	-0.35%	+4.30%	4.97TCr
REVOLUTION MEDICINES, INC.	+3.90%	-2.60%	+384.79%	+598.27%	3.81TCr
BEONE MEDICINES AG	-1.70%	+3.03%	+11.77%	+58.93%	3.53TCr
IQVIA HOLDINGS INC.	-2.01%	-1.30%	+30.02%	-6.71%	3.51TCr
CELLTRION, INC.	+0.06%	+1.56%	+4.41%	+27.42%	2.72TCr
ASCENDIS PHARMA A/S	+0.46%	-5.24%	-	-	1.61TCr
MEDPACE HOLDINGS, INC.	-0.04%	+0.42%	+70.80%	+121.10%	1.54TCr
EUROFINS SCIENTIFIC SE	+1.12%	+2.15%	+16.24%	+19.12%	1.39TCr
ICON PUBLIC LIMITED COMPANY	0.00%	+0.73%	+18.02%	-30.96%	1.3TCr
Average	-4.05%	-0.57%	+66.96%	+98.93%	2.71TCr
Weighted average by Cap.	-0.10%	-0.64%	+78.08%	+119.96%

	2024	2025
Net sales	-	-
Net income	-1.56Cr -51.28L -44.81L -41.35L -38.11L -71.84L -49Cr -73.43L -4.94Cr -1.94Cr -24Cr -1.93Cr -1.88Cr -83Cr	-2.78Cr -91.55L -80.01L -73.83L -68.05L -1.28Cr -88Cr -1.31Cr -8.82Cr -3.47Cr -43Cr -3.44Cr -3.36Cr -148.64Cr
Net Debt	-1.07Cr -35.14L -30.71L -28.34L -26.12L -49.24L -34Cr -50.33L -3.39Cr -1.33Cr -17Cr -1.32Cr -1.29Cr -57Cr	-2.01Cr -66.27L -57.92L -53.44L -49.26L -92.85L -64Cr -94.91L -6.39Cr -2.51Cr -31Cr -2.49Cr -2.43Cr -107.6Cr